ALT
Altimmune Inc
Halal Rating :
Last Price
$6.86
Last updated:
Market Cap
-
7D Change
1.18%
1 Year Change
-31.67%
Company Overview
Industries
Exchange
Next Earnings Date
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Their lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company also has other pipeline candidates in various stages of development.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $5000.0 | $24.78m | - | $6000.0 | 0.00% | 0.02% |
| June 30, 2024 | $5000.0 | $26.75m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $5000.0 | $26.8m | - | $1000.0 | 0.00% | 0.00% |
Company Impact
Help us evaluate Altimmune Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.